Matrix metalloproteinases during and outside of migraine attacks without aura

Cephalalgia

Volumn 30, Issue 3, 2010, Pages 303-310

  Ashina, M ^a   Tvedskov, J F ^a   Lipka, K ^a   Bilello, J ^b,c   Penkowa, M ^d   Olesen, J ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GLAXOSMITHKLINE   (United States)

^c Precision Human Biolaboratory   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Blood brain barrier; Concentration; External jugular vein; Matrix metalloproteinases; Migraine; Plasma; Tissue inhibitor of metalloproteases

Indexed keywords

GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; EXTERNAL JUGULAR VEIN; FEMALE; HUMAN; MALE; MIGRAINE WITHOUT AURA; PERMEABILITY; PROTEIN MICROARRAY;

ACUTE DISEASE; ADULT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; FEMALE; HUMANS; JUGULAR VEINS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MIGRAINE WITHOUT AURA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77956251264     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2009.01954.x     Document Type: Article

References (45)

1. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
2. Yong VW, Agrawal SM, Stirling DP. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007;4:580-9.
3. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007;85:2813-23.
4. Yong VW. The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 1999;8:255-68.
5. Goadsby PJ. Migraine pathophysiology. Headache 2005;45(Suppl. 1):S14-24.
6. Lauritzen M, Skyhøj Olsen T, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983;13:633-41.
7. Leão A A P. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-90.
8. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-52.
9. Sanchez-del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Curr Opin Neurol 2006;19:294-8.
10. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-42.
11. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004;113:1447-55.
12. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
13. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007;38:646-51.
14. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502-11.
15. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:185-8.
16. Leira R, Sobrino T, Rodriguez-Yáñez M, Blanco M, Arias S, Castillo J. Mmp-9 immunoreactivity in acute migraine. Headache 2007;47:698-702.
17. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 2008;48:135-9.
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain, 2nd edn. Cephalalgia 2004;24(Suppl. 1):9-160.
19. Perlee L, Christiansen J, Dondero R, Grimwade B, Lejnine S, Mullenix M, et al. Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics. Proteome Sci 2004;2:9.
20. Schweitzer B, Wiltshire S, Lambert J, O'Malley S, Kukanskis K, Zhu Z, et al. Inaugural article: immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. Proc Natl Acad Sci USA 2000;97:10113-19.
21. Dohmen C, Sakowitz OW, Fabricius M, Bosche B, Reithmeier T, Ernestus RI, et al. Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol 2008;63:720-8.
22. Kempski O. Cerebral edema. Semin Nephrol 2001;21:303-7.
23. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173-85.
24. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000;20:131-47.
25. Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001;280: H1241-8.
26. Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis TP. Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol 2002;283: H1531-7.
27. Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol 2005;289: H738-43.
28. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand Suppl 1987;113:1-40.
29. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43: S16-20.
30. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998;43:25-31.
31. Crawford JS, Konkol RJ. Familial hemiplegic migraine with crossed cerebellar diaschisis and unilateral meningeal enhancement. Headache 1997;37:590-3.
32. Arnold G, Reuter U, Kinze S, Wolf T, Einhaupl KM. Migraine with aura shows gadolinium enhancement which is reversed following prophylactic treatment. Cephalalgia 1998;18:644-6.
33. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-84.
34. Rosenberg GA, Estrada E, Kelley RO, Kornfeld M. Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci Lett 1993;160:117-19.
35. Savettieri G, Di Liegro I, Catania C, Licata L, Pitarresi GL, D'Agostino S, et al. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport 2000;11:1081-4.
36. Tilling T, Korte D, Hoheisel D, Galla HJ. Basement membrane proteins influence brain capillary endothelial barrier function in vitro. J Neurochem 1998;71:1151-7.
37. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020-30.
38. Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J. Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res 2005;79:522-34.
39. Penkowa M, Giralt M, Moos T, Thomsen PS, Hernandez J, Hidalgo J. Impaired inflammatory response to glial cell death in genetically metallothionein-I-and- II-deficient mice. Exp Neurol 1999;156:149-64.
40. Penkowa M, Hidalgo J. IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment. Exp Neurol 2000;163:72-84.
41. Penkowa M, Poulsen C, Carrasco J, Hidalgo J. M-CSF deficiency leads to reduced metallothioneins I and II expression and increased tissue damage in the brain stem after 6-aminonicotinamide treatment. Exp Neurol 2002;176:308-21.
42. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 2008;48:135-9.
43. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006;23:87-96.
44. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-4.
45. Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, Eriksson P. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 2006;259:530-6.